Expression and localization of tissue factor pathway inhibitor-2 in normal and atherosclerotic human vessels

被引:48
作者
Crawley, JTB
Goulding, DA
Ferreira, V
Severs, NJ
Lupu, F
机构
[1] Oklahoma Med Res Fdn, Cardiovasc Biol Res Program, Oklahoma City, OK 73104 USA
[2] Thrombosis Res Inst, London SW3 6LR, England
[3] Univ London Imperial Coll Sci Technol & Med, Ctr Mol Microbiol, London, England
[4] Univ Amsterdam, Acad Med Ctr, NL-1105 AZ Amsterdam, Netherlands
[5] Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, London, England
关键词
atherosclerosis; matrix metalloproteinases; tissue factor pathway inhibitor-2; plasmin; tissue factor;
D O I
10.1161/hq0102.101842
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Tissue factor pathway inhibitor-2 (TFPI-2) is a Kunitz-type, serine protease inhibitor with inhibitory activity toward activated factor XI, plasma kallikrein, plasmin, certain matrix metalloproteinases, and the tissue factor: activated factor VII complex. In this study, we investigated TFPI-2 expression and localization in normal and atherosclerotic human arteries by using in situ hybridization and immunohistochemical techniques. In healthy human blood vessels, TFPI-2 was detected in the vascular endothelium alone. In human atherosclerotic tissues. TFPI-2 expression was assigned to macrophages, T cells, endothelial cells, and smooth muscle cells. Western blot analysis for TFPI-2 confirmed its production by cultured human aortic smooth muscle cells, U937 cells (monocytes), and Jurkat (T cell) cell lines. Reverse transcription-polymerase chain reaction revealed similar TFPI-2 expression levels in both monocytes and macrophages in culture. Electron microscopic study with immunogold labeling revealed the association of TFPI-2 antigen with both the extracellular matrix and plasma membranes. TFPI-2 antigen was detected in some areas of atheroma that also stained positively for both tissue factor and factor VII. Moreover, detection of TFPI-2 in close spatial proximity to plasmin/plasminogen on macrophages, on endothelial cells, and in matrix-rich areas highlighted its possible functional significance in the regulation of plasmin activity and downstream proteolytic mechanisms that occur in the atherosclerotic lesion.
引用
收藏
页码:218 / 224
页数:7
相关论文
共 31 条
  • [1] ISOLATION AND CHARACTERIZATION OF PLACENTAL PROTEIN-PP5
    BOHN, H
    WINCKLER, W
    [J]. ARCHIV FUR GYNAKOLOGIE, 1977, 223 (03): : 179 - 186
  • [2] BUTZOW R, 1988, CLIN CHEM, V34, P1591
  • [3] Urokinase-generated plasmin activates matrix metalloproteinases during aneurysm formation
    Carmeliet, P
    Moons, L
    Lijnen, HR
    Baes, M
    Lemaitre, V
    Tipping, P
    Drew, A
    Eeckhout, Y
    Shapiro, S
    Lupu, F
    Collen, D
    [J]. NATURE GENETICS, 1997, 17 (04) : 439 - 444
  • [4] Collen D, 1999, THROMB HAEMOSTASIS, V82, P259
  • [5] Expression, localization, and activity of tissue factor pathway inhibitor in normal and atherosclerotic human vessels
    Crawley, J
    Lupu, F
    Westmuckett, AD
    Severs, NJ
    Kakkar, VV
    Lupu, C
    [J]. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2000, 20 (05) : 1362 - 1373
  • [6] Felez J, 1996, THROMB HAEMOSTASIS, V76, P577
  • [7] Tumor cell adhesion and migration supported by interaction of a receptor-protease complex with its inhibitor
    Fischer, EG
    Riewald, M
    Huang, HY
    Miyagi, Y
    Kubota, Y
    Mueller, BM
    Ruf, W
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1999, 104 (09) : 1213 - 1221
  • [8] MACROPHAGE FOAM CELLS FROM EXPERIMENTAL ATHEROMA CONSTITUTIVELY PRODUCE MATRIX-DEGRADING PROTEINASES
    GALIS, ZS
    SUKHOVA, GK
    KRANZHOFER, R
    CLARK, S
    LIBBY, P
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1995, 92 (02) : 402 - 406
  • [9] HALL SW, 1991, J BIOL CHEM, V266, P12329
  • [10] Tissue factor pathway inhibitor-2 is a novel inhibitor of matrix metalloproteinases with implications for atherosclerosis
    Herman, MP
    Sukhova, GK
    Kisiel, W
    Foster, D
    Kehry, MR
    Libby, P
    Schönbeck, U
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2001, 107 (09) : 1117 - 1126